INTRODUCTION {#sec0005}
============

Clinically node-positive bladder cancer (cN+ BC), an overall uncommon instance of newly-diagnosed BC, carries a poor prognosis. It is thus categorized as stage IV disease, and as a result these patients have been largely excluded from seminal clinical trials utilizing radical cystectomy (RC) \[[@ref001]\]. According to the National Comprehensive Cancer Network (NCCN), standard of care for cN+ BC is either chemotherapy (CT) or chemoradiotherapy (CRT) \[[@ref003]\].

The ambiguity in this recommendation is underscored by the lack of evidence regarding potential benefit of radiation therapy (RT) when added to systemic therapy for patients with cN+ BC. There are several reasons to surmise that addition of local therapy may lead to superior tumor control and thus potentially improved outcomes. First, randomized trials of other neoplasms have shown that CT alone is inadequate to control gross disease; local therapy is thus necessary to provide durable local control, which may translate into survival benefits \[[@ref004]\]. Second, analogous data in cN+ prostate cancer, which faces a similar debate as cN+ BC to this extent, have shown benefits to the addition of RT to androgen deprivation therapy \[[@ref006]\]. Third, there have been numerous publications illustrating the benefit of local therapy (in the form of surgical nodal dissection) in cN+ BC \[[@ref008]\]. Although those studies included only well-selected responders to CT (thus limiting applicability to all cases), they corroborated that a proportion of cN+ BC cases can indeed experience prolonged survival with aggressive local therapy.

Because cN+ BC is an overall uncommon circumstance with neither prospective nor high-volume retrospective data, this study was conducted using the large, contemporary dataset of the National Cancer Data Base (NCDB), in which we sought to evaluate practice patterns and outcomes in the management of this condition with respect to the two NCCN-recommended options, CT alone versus CRT.

MATERIALS AND METHODS {#sec0010}
=====================

This study analyzed the NCDB, which is a joint project of the Commission on Cancer (CoC) of the American College of Surgeons and the American Cancer Society, which consists of de-identified information regarding tumor characteristics, patient demographics, and patient survival for approximately 70% of the US population \[[@ref012]\]. The NCDB contains information not included in the Surveillance, Epidemiology, and End Results database, including details regarding use of systemic therapy and radiation dose. The data used in the study were derived from a de-identified NCDB file (2004--2013 dataset). The American College of Surgeons and the CoC have not verified and are neither responsible for the analytic or statistical methodology employed nor the conclusions drawn from these data by the investigators. As all patient information in the NCDB database is de-identified, this study was exempt from institutional review board evaluation.

Inclusion criteria for this study were patients aged \>18 years with newly-diagnosed cT~any~ cN1-3 cM0 BC. For inclusion, patients required use of chemotherapy with or without RT and recorded follow up date. Exclusion criteria included receipt of cystectomy, subtherapeutic RT (defined as doses \<55 Gray \[[@ref003]\]), and treatment with palliative intent. Patients were then divided into two categories based on the type of treatment administered: CT alone or CRT.

All statistical tests were two-sided, with a threshold of *p* \< 0.05 for statistical significance, and were performed using STATA (version 14, College Station, TX). Fisher's exact or *χ*^2^ test analyzed categorical proportions between groups in the non-parametric and parametric settings, respectively. Multivariable logistic regression modeling was utilized to determine characteristics predictive of receiving additional RT. The Kaplan-Meier method was used for survival analysis, and comparisons between the two treatment paradigms were performed with the log-rank test for all patients. Overall survival (OS) was defined as the interval between the date of diagnosis and the date of death or last contact. Multivariate Cox proportional hazards modeling was additionally used to identify variables associated with OS in the entire cohort. An additional subset analysis was performed to compare OS between patients treated with CRT, single-agent chemotherapy (sCT), or multi-agent chemotherapy (mCT). Lastly, to account for indication bias, propensity-score matching was used to compare patients treated with CRT to those receiving treatment with CT. Propensity matching is a method that creates quasicase/control pairs using a retrospective cohort in an effort to account for the recorded and unrecorded confounding variables \[[@ref016]\]. Propensity scores were calculated by use of a multivariable logistic regression model with the dependent variable being receipt of treatment with CRT vs treatment with CT and the independent variables being age, sex, T/N stage, histology, Charlson-Deyo comorbidity score, facility type, and insurance status. Patients were matched 1:1 to avoid potential bias from many-to-one matching, and to ensure balance of the covariates within the two cohorts, standardized differences were assessed with a value \<0.1 signifying an inconsequential imbalance \[[@ref016]\]. Survival rates were compared between the two matched groups with the log-rank test.

RESULTS {#sec0015}
=======

A complete flow diagram of patient selection is provided in [Fig. 1](#blc-3-blc170137-g001){ref-type="fig"}; 1,783 patients met study criteria. Of these, 1,388 (77.8%) were treated with CT alone, and 395 (22.2%) with CRT. [Table 1](#blc-3-blc170137-t001){ref-type="table"} displays clinical characteristics of the analyzed patients. Of note, cN1, cN2, and cN3 disease was present in 794 (44.5%), 790 (44.3%), and 199 (11.2%) patients. [Figure 2](#blc-3-blc170137-g002){ref-type="fig"} displays temporal trends of decreased frequency of CRT utilization as compared to CT alone.

![Patient selection diagram.](blc-3-blc170137-g001){#blc-3-blc170137-g001}

###### 

Baseline characteristics of patients with bladder cancer receiving either chemotherapy alone or chemoradiation

  Characteristic                               Chemotherapy,   Chemoradiation,    *P* value
  -------------------------------------------- --------------- ----------------- -----------
  Age                                                                            
    \<65                                       587 (42.3%)     120 (30.4%)         \<0.001
    65+                                        801 (57.7%)     275 (69.6%)       
  Sex                                                                            
    Male                                       995 (71.7%)     289 (73.2%)          0.564
    Female                                     393 (28.3%)     106 (26.8%)       
  Race                                                                           
    White                                      1167 (84.1%)    338 (85.6%)          0.582
    African American                           122 (8.8%)      36 (9.1%)         
    Hispanic                                   59 (4.3%)       11 (2.8%)         
    Asian/ Native American/ Pacific Islander   21 (1.5%)       7 (1.8%)          
    Not recorded                               19 (1.4%)       3 (0.8%)          
  T stage                                                                        
    T1                                         142 (10.2%)     23 (5.8%)            0.001
    T2                                         498 (35.9%)     141 (35.7%)       
    T3                                         202 (14.6%)     86 (21.8%)        
    T4                                         293 (21.1%)     84 (21.3%)        
    Not recorded                               253 (18.2%)     61 (15.4%)        
  N Stage                                                                        
    N1                                         590 (42.5%)     204 (51.6%)          0.006
    N2                                         637 (45.9%)     153 (38.7%)       
    N3                                         161 (11.6%)     38 (9.6%)         
  Histology                                                                      
    Urothelial carcinoma                       1198 (86.3%)    328 (83.0%)          0.154
    Squamous cell                              56 (4.0%)       22 (5.6%)         
    Adenocarcinoma                             35 (2.5%)       7 (1.8%)          
    Other                                      99 (7.1%)       38 (9.6%)         
  Charlson Deyo Score                                                            
    0                                          1051 (75.7%)    304 (77.0%)          0.610
    1--2                                       337 (24.3%)     91 (23.0%)        
  Facility Type                                                                  
    Academic                                   577 (41.6%)     120 (30.4%)         \<0.001
    Non academic                               811 (58.4%)     275 (69.6%)       
  Year of diagnosis                                                              
    2004--2008                                 488 (35.2%)     160 (40.5%)          0.051
    2009--2013                                 900 (64.8%)     235 (59.5%)       
  Insurance                                                                      
    Medicaid                                   108 (7.8%)      24 (6.1%)            0.001
    Medicare                                   750 (54.0%)     260 (65.8%)       
    Private                                    425 (30.6%)     87 (22.0%)        
    Not insured                                60 (4.3%)       13 (3.3%)         
    Other                                      45 (3.2%)       11 (2.8%)         
  Income                                                                         
    \< \$38000                                 242 (17.4%)     44 (11.1%)           0.013
    \$38000--\$47999                           336 (24.2%)     103 (26.1%)       
    \$48000--\$62999                           385 (27.7%)     111 (28.1%)       
    \$63000+                                   392 (28.2%)     132 (33.4%)       
    Not recorded                               33 (2.4%)       5 (1.3%)          

![Chemotherapy or chemoradiation utilization by year of diagnosis.](blc-3-blc170137-g002){#blc-3-blc170137-g002}

Multivariable logistic regression analysis was performed to evaluate factors independently associated with undergoing CRT over CT alone ([Table 2](#blc-3-blc170137-t002){ref-type="table"}). Factors statistically associated with receipt of RT in addition to CT included increasing T stage, squamous cell carcinoma (when compared to urothelial) histology, treatment at a non-academic facility, and higher socioeconomic status (*p* \< 0.05 for all).

###### 

Characteristics predictive for addition of radiotherapy to chemotherapy on multivariable logistic regression analysis

  Characteristic                                 Odds Ratio     95% Confidence Interval   *P* value
  -------------------------------------------- --------------- ------------------------- -----------
  Age                                                                                    
    \<65                                        1 (reference)                            
    65+                                             1.414            0.996--2.008           0.053
  Sex                                                                                    
    Male                                        1 (reference)                            
    Female                                          0.928            0.714--1.207           0.579
  Race                                                                                   
    White                                       1 (reference)                            
    African American                                1.344            0.881--2.052           0.170
    Hispanic                                        0.815            0.411--1.616           0.558
    Asian/ Native American/ Pacific Islander        1.145            0.470--2.790           0.766
    Not recorded                                    0.515            0.147--1.803           0.299
  T stage                                                                                
    T1                                          1 (reference)                            
    T2                                              1.740            1.067--2.837           0.026
    T3                                              2.834            1.682--4.775          \<0.001
    T4                                              1.869            1.115--3.132           0.018
    Not recorded                                    1.642            0.962--2.803           0.069
  N Stage                                                                                
    N1                                          1 (reference)                            
    N2                                              0.713            0.557--0.912           0.007
    N3                                              0.731            0.489--1.093           0.127
  Histology                                                                              
    Urothelial carcinoma                        1 (reference)                            
    Squamous cell                                   1.743            0.020--2.979           0.042
    Adenocarcinoma                                  0.827            0.354--1.933           0.661
    Other                                           1.442            0.961--2.163           0.077
  Charlson Deyo Score                                                                    
    0                                           1 (reference)                            
    1--2                                            0.868            0.659--1.142           0.311
  Facility Type                                                                          
    Academic                                    1 (reference)                            
    Non academic                                    1.643            1.282--2.107          \<0.001
  Year of diagnosis                                                                      
    2004--2008                                  1 (reference)                            
    2009--2013                                      0.821            0.642--1.050           0.115
  Insurance                                                                              
    Medicaid                                    1 (reference)                            
    Medicare                                        1.128            0.639--1.992           0.678
    Private                                         0.791            0.469--1.334           0.379
    Not insured                                     1.107            0.515--2.379           0.795
    Other                                           0.899            0.388--2.084           0.804
  Income                                                                                 
    \< \$38000                                  1 (reference)                            
    \$38000--\$47999                                1.764            1.172--2.653           0.006
    \$48000--\$62999                                1.648            1.103--2.461           0.015
    \$63000+                                        2.012            1.345--3.010           0.001
    Not recorded                                    0.718            0.259--1.987           0.524

Median follow-up was 13.8 months (interquartile range, 7.9--27.4 months). Kaplan-Meier estimates of OS between groups are illustrated in [Fig. 3A](#blc-3-blc170137-g003){ref-type="fig"}. The median OS in the CT only group was 13.8 months, whereas addition of RT to CT was associated with a survival improvement to 19.0 months (*p* \< 0.001). On subset analysis, CRT was associated with a median OS improvement when compared to patients treated with either sCT (19.0 vs. 11.5 months, *p* \< 0.001) or with mCT (19.0 vs. 14.0 months, *p* \< 0.001).

![Kaplan-Meier overall survival curves comparing those receiving chemoradiation versus chemotherapy alone (A), and in the propensity-matched population (B).](blc-3-blc170137-g003){#blc-3-blc170137-g003}

However, because the CT and CRT groups were imbalanced in terms of several variables, propensity matching was performed to evaluate OS between more balanced populations. When examining OS between both propensity matched cohorts ([Fig. 3B](#blc-3-blc170137-g003){ref-type="fig"}), OS differences between cohorts persisted (*p* \< 0.001).

Multivariate Cox proportional hazards modeling examining independent predictors of OS is displayed in [Table 3](#blc-3-blc170137-t003){ref-type="table"}. There were several factors associated with worse OS: use of CT alone (when compared to CRT), female gender, T3 or T4 disease (when compared to T1), N3 status (when compared to N1), a Charlson Deyo comorbidity score of 1--2 (compared to a score of 0), or squamous cell histology (when compared to urothelial carcinoma) (*p* \< 0.05 for all). Of note, age and treatment facility type did not independently correlate with OS.

###### 

Cox multivariate analysis of factors predictive of overall survival in the entire cohort

  Characteristic                                     HR            95% CI      *P* value
  -------------------------------------------- --------------- -------------- -----------
  Treatment group                                                             
    Chemotherapy                                1 (reference)                 
    Chemoradiation                                  0.718       0.628--0.819    \<0.001
  Age                                                                         
    \<65                                        1 (reference)                 
    65+                                             1.094       0.935--1.280     0.264
  Sex                                                                         
    Male                                        1 (reference)                 
    Female                                          1.287       0.143--1.448    \<0.001
  Race                                                                        
    White                                       1 (reference)                 
    African American                                0.989       0.814--1.201     0.913
    Hispanic                                        0.626       0.455--0.861     0.004
    Asian/ Native American/ Pacific Islander        0.550       0.329--0.920     0.023
    Not recorded                                    1.054       0.635--1.749     0.840
  T stage                                                                     
    T1                                          1 (reference)                 
    T2                                              1.141       0.928--1.403     0.211
    T3                                              1.349       1.073--1.700     0.011
    T4                                              1.765       1.418--2.200    \<0.001
    Not recorded                                    1.250       0.995--1.571     0.055
  N Stage                                                                     
    N1                                          1 (reference)                 
    N2                                              1.046       0.933--1.172     0.439
    N3                                              1.365       1.138--1.636     0.001
  Histology                                                                   
    Urothelial carcinoma                        1 (reference)                 
    Squamous cell                                   1.852       1.425--2.408    \<0.001
    Adenocarcinoma                                  0.845       0.601--1.188     0.333
    Other                                           1.446       1.191--1.756    \<0.001
  Charlson Deyo Score                                                         
    0                                           1 (reference)                 
    1--2                                            1.242       1.100--1.407     0.001
  Facility Type                                                               
    Academic                                    1 (reference)                 
    Non academic                                    1.041       0.931--1.163     0.485
  Year of diagnosis                                                           
    2004--2008                                  1 (reference)                 
    2009--2013                                      0.892       0.795--1.002     0.053
  Insurance                                                                   
    Medicaid                                    1 (reference)                 
    Medicare                                        0.960       0.748--1.232     0.751
    Private                                         0.887       0.709--1.110     0.296
    Not insured                                     1.068       0.767--1.456     0.697
    Other                                           1.083       0.748--1.567     0.673
  Income                                                                      
    \< \$38000                                  1 (reference)                 
    \$38000--\$47999                                0.992       0.834--1.180     0.929
    \$48000--\$62999                                1.062       0.896--1.258     0.491
    \$63000+                                        0.949       0.797--1.129     0.554
    Not recorded                                    1.672       1.165--2.399     0.005

DISCUSSION {#sec0020}
==========

The management of cN+ BC is poorly defined, largely owing to its uncommon nature. There are numerous findings and reflections from this analysis of a contemporary national database, the largest of its kind to date. In the United States, CRT is underutilized as compared to CT alone, but was independently associated with a survival benefit in these patients. These results have implications not only for patient management and counseling, but also for the NCCN recommendations.

Because CRT and CT alone are both recommended in the management of this population, the major goal of this study was to evaluate outcomes between both definitive treatments. The findings of independently higher OS with CRT, despite a substantially lower sample size (just 22.2% of patients received CRT), is even more noteworthy for one major reason described in other work \[[@ref019]\]. As compared with CT alone, RT was likely added for "higher-risk" disease with presumably some degree of poor-prognostic features. Indeed, although CRT was utilized in older (65 + years old, *p* = 0.053) individuals with more advanced T- classification, and non-urothelial histology, addition of radiotherapy to CT independently associated with improved survival in this "higher-risk" cohort. This further suggests that, in an evenly matched population, the OS benefit with the addition of RT to CT may be even greater than the absolute 5.2 month median OS benefit described here.

In light of the aforementioned surgical series and other data \[[@ref008]\], CRT may be advantageous because development of a (pathologic) complete response has been linked with improved prognosis. This likely reflects the presence of favorable tumor biology, but efforts to increase the (pathologic) complete response rate are nevertheless warranted and are being attempted in other neoplasms \[[@ref020]\]. Furthermore, more aggressive therapy along with CT may allow well-selected responders to undergo RC and potentially eliminate all traces of gross disease, which as mentioned above have resulted in good outcomes. In a NCDB study of cN+ BC (that did not evaluate radiotherapy), addition of neoadjuvant CT to RC was associated with a survival improvement over RC alone, likely relating to well-selected patients but also potentially owing to better sterilization of existing microscopic disease prior to gross total resection \[[@ref021]\]. Finally, it has been documented in other disease sites that CT alone is unable to eradicate gross disease \[[@ref004]\]. The results of this study are very much in line with those of prostate cancer, in which the addition of RT to systemic therapy has been demonstrated to offer substantial survival benefits in patients with node positive disease \[[@ref006]\].

From this study, an unresolved issue is administration of CT and RT sequentially versus concurrently. A caveat of our study is the lack of stratification in sequencing of both modalities, and to this extent further work must be performed. Additionally, it is difficult to address herein whether cN1, cN2, or cN3 patients benefit from CRT, owing to sample size issues in analyzing sub-cohorts and especially the low numbers of cN3 patients.

Optimal radiotherapy techniques in cN+ BC are not well-defined apart from small series \[[@ref022]\]. Although three-dimensional techniques are clearly preferred, we propose that inverse-planned techniques such as intensity-modulated radiotherapy (IMRT) or volumetric-modulated arc therapy (VMAT) may be uniquely suited for cN+ CRT. This largely centers on the ability to perform simultaneous integrated boosting of grossly involved lymph nodes (and gross bladder disease) while delivering tumoricidal doses to non-clinically involved areas of lymphatics, and low doses to surrounding organs-at-risk. In general BC cohorts, both IMRT and VMAT display lower bowel doses over three-dimensional conformal radiotherapy (3DCRT) \[[@ref023]\]. Moreover, IMRT is also associated with low rates of toxicities, potentially as a result of these dosimetric advantages over 3DCRT \[[@ref024]\]. However, a caveat to utilizing IMRT in BC relates to interfractional changes in organ motion, especially with regard to bladder filling. For this reason, image-guided radiotherapy is also recommended whenever possible.

There are several limitations of this investigation. Selection biases in this and any retrospective study are readily recognized. Another major caveat to these data is the lack of confirmation whether patients had histologic corroboration of cN+ disease. However, as acknowledged by the NCCN, this is not feasible in many cases \[[@ref003]\]; to this extent, although it is unknown how many patients had positron emission tomography-based initial workup, it may be useful in cases for which biopsy is not feasible. Next, the NCDB does not keep track of several noteworthy variables, such as specific CT agents and number of cycles completed, RT fields (including nodal volumes), reasons for a particular treatment, immune/biologic therapies, and salvage treatment, which could all confound conclusions presented herein. It also does not record other endpoints such as tolerance of therapy (including premature cessation of CT), cancer-specific survival, and local/regional control. Nevertheless, the caveats herein do not obviate the need for further investigation to corroborate these conclusions.

CONCLUSIONS {#sec0025}
===========

This is the largest study to date examining the practice patterns and outcomes for patients with cN+ BC. The results suggest that although bimodality therapy is currently underutilized, and more often given to "higher-risk" patients, the addition of radiation therapy to chemotherapy may improve survival for patients with cN+ BC. Other investigations are recommended to further elucidate the optimal treatment paradigm for patients with cN+ BC.
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